Privium Fund Management B.V. Trims Stock Holdings in Zai Lab Limited (NASDAQ:ZLAB)

Privium Fund Management B.V. decreased its holdings in shares of Zai Lab Limited (NASDAQ:ZLAB) by 14.2% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 185,062 shares of the company’s stock after selling 30,562 shares during the quarter. Zai Lab comprises approximately 1.1% of Privium Fund Management B.V.’s portfolio, making the stock its 20th biggest holding. Privium Fund Management B.V.’s holdings in Zai Lab were worth $4,847,000 as of its most recent SEC filing.

Several other institutional investors have also recently made changes to their positions in ZLAB. Janus Henderson Group PLC grew its position in shares of Zai Lab by 34.2% in the third quarter. Janus Henderson Group PLC now owns 8,760,074 shares of the company’s stock valued at $211,488,000 after purchasing an additional 2,232,507 shares in the last quarter. Wellington Management Group LLP boosted its stake in Zai Lab by 18.4% in the 3rd quarter. Wellington Management Group LLP now owns 8,436,606 shares of the company’s stock worth $203,660,000 after purchasing an additional 1,312,115 shares during the period. Bamco Inc. NY grew its holdings in Zai Lab by 6.4% during the 3rd quarter. Bamco Inc. NY now owns 1,906,520 shares of the company’s stock valued at $46,023,000 after buying an additional 113,869 shares in the last quarter. Principal Financial Group Inc. purchased a new position in Zai Lab during the 4th quarter valued at about $46,172,000. Finally, Allianz Asset Management GmbH increased its position in shares of Zai Lab by 188.6% during the fourth quarter. Allianz Asset Management GmbH now owns 1,505,866 shares of the company’s stock valued at $39,442,000 after buying an additional 984,041 shares during the period. Hedge funds and other institutional investors own 41.65% of the company’s stock.

Zai Lab Price Performance

Shares of ZLAB opened at $37.92 on Wednesday. Zai Lab Limited has a 1-year low of $13.48 and a 1-year high of $39.61. The company has a market capitalization of $4.16 billion, a P/E ratio of -13.69 and a beta of 1.08. The firm’s 50 day simple moving average is $29.97 and its 200 day simple moving average is $27.45.

Zai Lab (NASDAQ:ZLAB) last posted its quarterly earnings data on Thursday, February 27th. The company reported ($0.80) earnings per share for the quarter, missing the consensus estimate of ($0.61) by ($0.19). Zai Lab had a negative net margin of 76.14% and a negative return on equity of 36.97%. The company had revenue of $109.07 million for the quarter, compared to analysts’ expectations of $110.15 million. On average, equities analysts anticipate that Zai Lab Limited will post -2.58 earnings per share for the current year.

Insider Buying and Selling at Zai Lab

In other Zai Lab news, CEO Ying Du sold 50,000 shares of the company’s stock in a transaction that occurred on Friday, February 28th. The stock was sold at an average price of $34.47, for a total value of $1,723,500.00. Following the completion of the sale, the chief executive officer now owns 494,117 shares of the company’s stock, valued at $17,032,212.99. This represents a 9.19 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, insider Frazor Titus Edmondson III sold 14,544 shares of Zai Lab stock in a transaction that occurred on Friday, February 28th. The stock was sold at an average price of $32.98, for a total transaction of $479,661.12. Following the transaction, the insider now directly owns 14,328 shares in the company, valued at $472,537.44. This trade represents a 50.37 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 122,127 shares of company stock worth $4,024,442 over the last 90 days. Corporate insiders own 13.88% of the company’s stock.

Analysts Set New Price Targets

ZLAB has been the subject of a number of analyst reports. Bank of America restated a “neutral” rating and issued a $36.10 price objective (up from $29.00) on shares of Zai Lab in a research report on Monday, March 3rd. Scotiabank assumed coverage on shares of Zai Lab in a report on Friday, March 7th. They issued a “sector outperform” rating and a $55.00 price target for the company. JPMorgan Chase & Co. upped their price target on shares of Zai Lab from $44.00 to $51.00 and gave the stock an “overweight” rating in a report on Thursday, March 13th. Finally, Cantor Fitzgerald raised Zai Lab to a “strong-buy” rating in a research note on Tuesday, March 4th.

Zai Lab Company Profile

Zai Lab Limited develops and commercializes therapies to treat oncology, autoimmune disorders, infectious diseases, and neuroscience. Its commercial products include Zejula, an orally administered poly polymerase 1/2 inhibitor; Optune, a cancer therapy that uses electric fields tuned to specific frequencies to kill tumor cells; NUZYRA for acute bacterial skin and skin structure infections, and community acquired bacterial pneumonia; Qinlock to treat gastrointestinal stromal tumors, and VYVGART, a human IgG1 antibody fragment for myesthenia gravis.